A total of 18 patients were excluded because of secondary ILD of known etiology, lack of measurement of CRP or Alb, not using platinum‐based chemotherapy as first‐line treatment, no chemotherapy, transferring to another hospital before chemotherapy, infectious condition, administering gemcitabine, or using erlotinib. This evidence concerns the gene CRP and interstitial lung disease.